BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 25, 2026
Breaking News: Ongoing coverage of the Ebola outbreakBreaking News: Ongoing coverage of the Ebola outbreakBreaking News: Ongoing coverage of the Ebola outbreak
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Pill over molecule structures
ACS Fall 2022

Nimbus Therapeutics details discovery, discloses structure of selective TYK2 inhibitor NDI-034858

Aug. 30, 2022
The structure of a potent and selective TYK2 inhibitor, NDI-034858 (NTX-973), which was found clinically effective in autoimmune and inflammatory diseases, was disclosed for the first time by researchers from Nimbus Therapeutics LLC.
Read More
EMCHD 2022

Anti-C1q Fc-muTP-L309C is a potent modulator of classic component pathway activation

Aug. 30, 2022
Researchers from CSL Behring LLC have investigated the inhibitory properties of an rFc hexamer, named Fc-muTP-L309C, as a modulator of the classic component pathway activation.
Read More
Hematologic

Scinnohub Pharmaceutical identifies new plasmin inhibitors

Aug. 30, 2022
Scinnohub Pharmaceutical Co. Ltd. has presented plasmin inhibitors reported to be useful for the treatment of hemorrhage.
Read More
Human NK cell
2022 International Myeloma Workshop

Onk Therapeutics presents data on CD38-targeting ONKT-102 CAR-NK cells for MM

Aug. 30, 2022
Chimeric antigen receptor (CAR) T-cell therapy is effective in the treatment of multiple myeloma (MM), but its toxicity and complex manufacturing limit their broad use.
Read More
Immuno-oncology

GI Cell collaborates with HK Inno.N to research and develop CAR-NK candidates

Aug. 30, 2022
GI Cell Inc. has entered into a research and development collaboration for allogeneic chimeric antigen receptor (CAR)-natural killer (NK) candidates with HK Inno.N Corp.
Read More
Lab research with pipette, microsope
Cancer

Yaoya Technology patents new BTK inhibitors

Aug. 30, 2022
Yaoya Technology (Shanghai) Co. Ltd. has disclosed tyrosine-protein kinase BTK inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, lupus erythematosus, lupus nephritis, multiple sclerosis, asthma and Sjogren's syndrome.
Read More
Cancer

Shanghai Apeiron Biotechnology synthesizes new TIPARP inhibitors

Aug. 30, 2022
Shanghai Apeiron Biotechnology Co. Ltd. has disclosed triheterocyclic compounds acting as protein mono-ADP-ribosyltransferase TIPARP inhibitors and thus reported to be useful for the treatment of cancer.
Read More
Multiple myeloma illustration
2022 International Myeloma Workshop

BMF-219 demonstrates efficacy in DLBCL and MM preclinical models

Aug. 30, 2022
Researchers from Biomea Fusion Inc. presented preclinical data for the novel covalent menin inhibitor, BMF-219, after being evaluated in models of diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM).
Read More
Lab glassware and scientist
Cancer

Applied Pharmaceutical Science divulges RET inhibitors

Aug. 30, 2022
Applied Pharmaceutical Science Inc. has described new proto-oncogene tyrosine-protein kinase receptor Ret, (V804M mutant) and (G810R mutant) inhibitors reported to be useful for the treatment of cancer and irritable bowel syndrome.
Read More
Biomarkers

CSMD1 expression is linked to poor prognosis in patients with glioma

Aug. 30, 2022
The prognostic role of complement inhibitor CSMD1 was assessed in 1,507 patients with glioma from three different datasets. Results of the bioinformatical analysis suggested that high expression of CSMD1 was associated with increased overall survival and disease-free survival, as well as lower tumor grade.
Read More
Previous 1 2 … 1392 1393 1394 1395 1396 1397 1398 1399 1400 … 18107 18108 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 25, 2026.
  • Blue brain with computer chip

    Have brain-computer interfaces finally arrived?

    BioWorld
    More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 23, 2026
  • Patient using Neuracle NEO system

    2026 marks critical turning point for BCI technology

    BioWorld
    Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...
  • Cortec Brain Interchange BCI system

    Brain-computer interfaces are here but long road ahead

    BioWorld
    The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing